Search results
Results from the WOW.Com Content Network
Marion Merrell Dow and its predecessor Marion Laboratories was a U.S. pharmaceutical company based in Kansas City, Missouri, from 1950 until 1996.. The company specialized in bringing to market drugs that had been discovered but unmarketed by other companies including Cardizem which treats arrhythmias and high blood pressure, Carafate (an ulcer treatment), Gaviscon (an antacid), Seldane (a ...
Published annually since 1993, the Express Scripts Drug Trend Report provides detailed analysis of prescription drug costs and utilization. [20] [58] Now a web-based version, the Drug Trend Report is developed and published by the Express Scripts Research & New Solutions Lab with contributors from researchers, clinicians and others. [59]
King Pharmaceuticals obtained about twenty smaller branded drugs from the start up of the company until it went public in June 1998. The King Pharmaceuticals subsidiary Monarch Pharmaceuticals acquired one of its most profitable branded drugs, Altace, later the same year on December 18, 1998 from Hoechst Marion Roussel .
The budget approved Thursday in the Missouri House would provide a 3.2% pay raise for state workers and a 2% boost to higher education institutions as well as fund major upgrades on Interstate 44 ...
Missouri abortion rights supporters hold a celebratory press conference outside the state Capitol after the Missouri Supreme Court ruled that Amendment 3 can remain on the ballot.
Benzodiazepines typically start working very quickly — their anti-anxiety effects may come on in less than an hour. They work so well (short-term) that many people don’t want to stop taking them.
Prescription drug monitoring programs, or PDMPs, are an example of one initiative proposed to alleviate effects of the opioid crisis. [1] The programs are designed to restrict prescription drug abuse by limiting a patient's ability to obtain similar prescriptions from multiple providers (i.e. “doctor shopping”) and reducing diversion of controlled substances.
In December 2012, The New York Times, in an article on Mallinckrodt's main drug H.P. Acthar Gel, [a] reported: "How the price of this drug rose so far, so fast is a story for these troubled times in American health care—a tale of aggressive marketing, questionable medicine and, not least, out-of-control costs". [31]